These two genetic alternations may be identified simultaneously or JAK2 mutations may be detected in the setting of previously diagnosed CML treated with TKI and the BCR::ABL1 translocation ultimately developing in patients with a long history of JAK2-mutated MPN. This evidence concerns the gene JAK2 and myeloproliferative disorder.